XML 30 R15.htm IDEA: XBRL DOCUMENT v3.26.1
Supplemental Income Statement Information
 3 Months Ended
Mar. 28, 2026
Supplemental Income Statement Elements [Abstract]  
Supplemental Income Statement Information Supplemental Income Statement Information
Disaggregated Revenues
Revenues by type are as follows:
Three months ended
(In millions)March 28, 2026March 29, 2025
Revenues
Consumables
$4,722 $4,354 
Instruments
1,555 1,626 
Services
4,728 4,384 
Consolidated revenues$11,005 $10,364 
Revenues by geographic region based on customer location are as follows:
Three months ended
(In millions)March 28, 2026March 29, 2025
Revenues
North America
$5,705 $5,513 
Europe
2,957 2,624 
Asia-Pacific
1,970 1,891 
Other regions
372 337 
Consolidated revenues$11,005 $10,364 
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions.
Revenues by business are as follows:
Three months ended
(In millions)
March 28, 2026March 29, 2025
Revenues


Biosciences
$981 $993 
Genetic sciences
655 677 
BioProduction
893 671 
Other
107 — 
Life Sciences Solutions
2,636 2,341 
Chromatography and mass spectrometry
798 773 
Chemical analysis
285 286 
Electron microscopy
633 659 
Analytical Instruments
1,716 1,718 
Clinical diagnostics
271 263 
ImmunoDiagnostics
230 217 
Microbiology
160 152 
Transplant diagnostics
121 113 
Healthcare market channel
430 474 
Elimination of intrasegment revenues
(71)(72)
Specialty Diagnostics
1,142 1,148 
Laboratory products
569 582 
Research and safety market channel
1,827 1,727 
Pharma services
1,741 1,607 
Clinical research
2,128 1,939 
Elimination of intrasegment revenues and other
(228)(214)
Laboratory Products and Biopharma Services
6,036 5,640 
Elimination of intersegment revenues
(524)(482)
Consolidated revenues$11,005 $10,364 
Restructuring and Other Costs
In the first three months of 2026, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2026, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.
As of May 1, 2026, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services segment, that it expects will result in additional charges of approximately $290 million, primarily in 2026, and expects to identify additional actions in future periods.
Restructuring and other costs are as follows:
Three months ended
(In millions)March 28, 2026
Life Sciences Solutions
$9 
Analytical Instruments
4 
Laboratory Products and Biopharma Services
33 
Corporate
3 
$49 
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.
(In millions)Total (a)
Balance at December 31, 2025$70 
Net restructuring charges incurred in 2026 (b)
34 
Payments
(37)
Currency translation and other(2)
Balance at March 28, 2026$65 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $15 million of net charges, principally $14 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services segment.
The company expects to pay accrued restructuring costs primarily through 2026.
Earnings per Share
The company’s earnings per share are as follows:
Three months ended
March 28,March 29,
(In millions except per share amounts)20262025
Net income attributable to Thermo Fisher Scientific Inc.$1,651 $1,507 
Basic weighted average shares372 378 
Plus effect of: stock options and restricted stock units1 1 
Diluted weighted average shares373 379 
Basic earnings per share$4.44 $3.99 
Diluted earnings per share$4.43 $3.98 
Antidilutive stock options excluded from diluted weighted average shares
3 3